A comprehensive analysis of the incidence of chromosomal abnormalities in hematologic malignancies post-COVID-19 outbreak in King Chulalongkorn Memorial Hospital, Thailand
References
- Jaiswal A, Shrivastav S, Kushwaha HR, Chaturvedi R, Singh RP. Oncogenic potential of SARS-CoV-2-targeting hallmarks of cancer pathways. Cell Commun Signal. 2024; 22:447. doi: 10.1186/s12964-024-01818-0
- Wiese W, Barczuk J, Racinska O, Siwecka N, Rozpedek-Kaminska W, Slupianek A, et al. PI3K/Akt/mTOR signaling pathway in blood malignancies-new therapeutic possibilities. Cancers (Basel). 2023; 15:5297.
- Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023; 22:138. doi: 10.1186/s12943-023-01827-6
- Ferreira AV, Netea MG. Hematopoietic memory of severe COVID-19 infection. Cell Res. 2024; 34:187–8.
- Jafarzadeh A, Gosain R, Mortazavi SMJ, Nemati M, Jafarzadeh S, Ghaderi A. SARS-CoV-2 infection: a possible risk factor for incidence and recurrence of cancers. Int J Hematol Oncol Stem Cell Res. 2022; 16:117–27.
- Jahankhani K, Ahangari F, Adcock IM, Mortaz E. Possible cancer-causing capacity of COVID-19: is SARS-CoV-2 an oncogenic agent? Biochimie. 2023; 213:130–8.
- Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022; 36:1703–19.
- Akkari YMN, Baughn LB, Dubuc AM, Smith AC, Mallo M, Dal Cin P, et al. Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood. 2022; 139:2273–84.
- Lestringant V, Guermouche-Flament H, Jimenez-Pocquet M, Gaillard JB, Penther D. Cytogenetics in the management of hematological malignancies: an overview of alternative technologies for cytogenetic characterization. Curr Res Transl Med. 2024; 72:103440.
- Cavalca F, Renso R, Zambrotta GPM, Gambacorti-Passerini C, Elli EM. Being a myeloproliferative patient in COVID-19 Era: the MYTICO Study. Front Oncol. 2021; 11:668261. doi: 10.3389/fonc.2021.668261
- Baransel Kamaz A, Mullally A. COVID-19 and myeloproliferative neoplasms: some considerations. Leukemia. 2021; 35: 279–81.
- Rapti V, Tsaganos T, Vathiotis IA, Syrigos NK, Li P, Poulakou G. New insights into SARS-CoV-2 and cancer cross-talk: does a novel oncogenesis driver emerge? Vaccines (Basel). 2022; 10:1607.
- Costa BA, da Luz KV, Campos SEV, Lopes GS, Leitao JPV, Duarte FB. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? a case series and review of the literature. Hematol Transfus Cell Ther. 2022; 44:26–31.
- Panico P, Ostrosky-Wegman P, Salazar AM. The potential role of COVID-19 in the induction of DNA damage. Mutat Res Rev Mutat Res. 2022; 789:108411. doi: 10.1016/j.mrrev.2022.108411
- Ogarek N, Oboza P, Olszanecka-Glinianowicz M, Kocelak PSARS-CoV-2 infection as a potential risk factor for the development of cancer. Front Mol Biosci. 2023; 10:1260776. doi: 10.3389/fmolb.2023.1260776
- Victor J, Deutsch J, Whitaker A, Lamkin EN, March A, Zhou P, et al. SARS-CoV-2 triggers DNA damage response in Vero E6 cells. Biochem Biophys Res Commun. 2021; 579:141–5.
Language: English
Page range: 194 - 201
Published on: Jun 30, 2026
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Related subjects:
© 2026 Montakarn Tansatit, Nutcharee Jongpornchai, Suwannee Songchart, Kittipornpan Krajokpap, Hudadini Da-oh, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.